海翔药业(002099.SZ)：NWRD08注射液完成Ⅱ期临床首例受试者入组

Core Viewpoint - The company has announced the initiation of the Phase II clinical trial for NWRD08 injection, a therapeutic vaccine for HPV16/18 positive cervical high-grade squamous intraepithelial lesions (HSIL), marking a significant advancement in cancer treatment in China [1] Group 1: Company Developments - The company has received investment from Beijing Guoxin Haixiang Equity Investment Partnership (Limited Partnership) for its subsidiary, Nuo Wei Biotechnology (Wuxi) Co., Ltd [1] - The Phase II clinical trial for NWRD08 has officially started at Peking Union Medical College Hospital and several other hospitals, with the first subject enrolled and treated [1] Group 2: Product Details - NWRD08 injection is the first domestically developed therapeutic nucleic acid drug targeting HPV16/18 positive HSIL, designed to activate specific T-cell immunity to eliminate infected cells [1] - Unlike preventive HPV vaccines, NWRD08 specifically targets patients already infected with HPV and exhibiting related lesions, aiming to halt disease progression at its source [1] - The therapy allows female patients to retain their cervix compared to traditional surgical removal methods [1]